Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 7, 2025, discloses transactions in company shares by board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 78,400 people across 80 countries.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of insider trading activity.
Material Changes and Transaction Details
The filing reports two share sale transactions executed on August 7, 2025, by Martin Holst Lange, Executive Vice President:
- Transaction 1: Sale of 74 shares at DKK 316.75 per share (Total: DKK 23,439.50) via Citigroup Global Markets Europe AG.
- Transaction 2: Sale of 13,950 shares at DKK 316.48 per share (Total: DKK 4,414,898.43) outside a trading venue.
- Aggregate Activity: Total of 14,024 shares sold for an aggregate value of approximately DKK 4,438,337.93.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. It serves solely as a notification of the specific insider transactions listed above.
Investor Verification Checklist
- Verify the total number of shares sold by Executive Vice President Martin Holst Lange (14,024 shares).
- Confirm the execution date of the transactions (August 7, 2025).
- Review the aggregate transaction value (approx. DKK 4.44 million).
- Note that this filing contains no operational or financial performance updates for the period.